Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. This was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. Not applicable since it is not an interventional study.

中文翻译：

---

抗衰老前列腺癌患者的疲劳患病率及其对生活质量的影响：至关重要的研究

疲劳是癌症患者中最普遍的症状之一。具体而言，在转移性去势抵抗性前列腺癌（mCRPC）患者中，疲劳是与当前治疗相关的最常见不良事件。这项研究的目的是描述常规临床实践中CRPC患者的疲劳患病率及其对生活质量（QoL）的影响。这是一项横断面，多中心的研究。具备高风险非转移性（M0）CRPC和转移性（M1）CRPC（mCRPC）的男性无化学经验的成年人是合格的。使用简要疲劳量表（BFI）测量疲劳，并使用前列腺癌患者的癌症治疗功能评估问卷（FACT-P）和FACT-General（FACT-G）问卷评估QoL。使用Mann-Whitney或Kruskal-Wallis检验（非参数分布），T检验或ANOVA（参数分布）以及Fisher或卡方检验（分类变量）分析数据。该研究共纳入235名合格患者（74名[31.5％] M0； 161名[68.5％] M1）。74％的人出现疲劳，其中38.5％的患者报告中度至重度疲劳。FACT-G和FACT-P的平均总分分别为77.6±16.3和108.7±21.4，在CRPC M0和CRPC M1子组之间没有差异。疲劳强度与FACT-G / P得分降低相关，各组之间无差异。在151例具有可用治疗数据的mCRPC患者中，用阿比特龙-泼尼松≥3个月治疗的患者显示出疲劳强度（p = 0.043）和干扰（p = 0）显着降低。04）与传统激素疗法（HT）相比。≥3个月的阿比特龙泼尼松患者的FACT-G / P评分明显高于HT的患者（分别为p = 0.046和0.018）。我们的数据显示，在未接受化学疗法的CRPC患者中，疲劳的发生率和强度较高，并且对QoL产生影响。不论是否存在转移，更大的疲劳感和更少的QoL都有相关性。与传统HT相比，未接受过化学治疗的mCRPC化疗患者接受了超过3个月的醋酸阿比特龙酯加泼尼松治疗，其疲劳和QoL有所改善。不适用，因为它不是干预性研究。我们的数据显示，在未接受化学疗法的CRPC患者中，疲劳的发生率和强度较高，并且对QoL产生影响。不论是否存在转移，更大的疲劳感和更少的QoL都有相关性。与传统HT相比，未接受过化学治疗的mCRPC化疗患者接受了超过3个月的醋酸阿比特龙酯加泼尼松治疗，其疲劳和QoL有所改善。不适用，因为它不是干预性研究。我们的数据显示，在未接受化学疗法的CRPC患者中，疲劳的发生率和强度较高，并且对QoL产生影响。不论是否存在转移，更大的疲劳感和更少的QoL都有相关性。与传统HT相比，未接受过化学治疗的mCRPC化疗患者接受了超过3个月的醋酸阿比特龙酯加泼尼松治疗，其疲劳和QoL有所改善。不适用，因为它不是干预性研究。